D. E. Shaw & Co., Inc. Tg Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 89,602 shares of TGTX stock, worth $1.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

89,602

Previous 11,200 700.02%

Holding current value

$1.68 Million

Previous $191,000 613.09%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$13.02 - $21.3 $2.25 Million - $3.69 Million	-173,176 Reduced 65.9%	89,602 $1.36 Million
Q4 2023 Feb 14, 2024	BUY	$6.68 - $18.81 $852,241 - $2.4 Million	127,581 Added 94.37%	262,778 $4.49 Million
Q3 2023 Nov 14, 2023	SELL	$8.36 - $26.5 $12 Million - $38.2 Million	-1,440,274 Reduced 91.42%	135,197 $1.13 Million
Q2 2023 Aug 14, 2023	BUY	$15.48 - $35.0 $11.5 Million - $26 Million	741,694 Added 88.96%	1,575,471 $39.1 Million
Q1 2023 May 15, 2023	SELL	$10.23 - $19.34 $14 Million - $26.5 Million	-1,370,453 Reduced 62.17%	833,777 $12.5 Million

Q4 2022 Feb 14, 2023	BUY	$5.01 - $11.83 $7.53 Million - $17.8 Million	1,503,230 Added 214.44%	2,204,230 $26.1 Million
Q3 2022 Nov 14, 2022	SELL	$4.57 - $8.4 $2.34 Million - $4.31 Million	-512,778 Reduced 42.25%	701,000 $4.15 Million
Q2 2022 Aug 15, 2022	BUY	$3.74 - $10.66 $3.53 Million - $10.1 Million	943,427 Added 348.96%	1,213,778 $5.16 Million
Q1 2022 May 16, 2022	BUY	$7.81 - $20.45 $1.98 Million - $5.18 Million	253,317 Added 1487.13%	270,351 $2.57 Million
Q4 2021 Feb 14, 2022	SELL	$15.2 - $35.51 $36,540 - $85,366	-2,404 Reduced 12.37%	17,034 $324,000
Q3 2021 Nov 15, 2021	SELL	$21.78 - $40.45 $3.01 Million - $5.59 Million	-138,142 Reduced 87.66%	19,438 $647,000
Q2 2021 Aug 16, 2021	SELL	$32.5 - $48.96 $12.3 Million - $18.5 Million	-377,421 Reduced 70.55%	157,580 $6.11 Million
Q1 2021 May 17, 2021	SELL	$41.61 - $54.3 $13.9 Million - $18.1 Million	-333,478 Reduced 38.4%	535,001 $25.8 Million
Q4 2020 Feb 16, 2021	BUY	$25.27 - $54.9 $8.72 Million - $18.9 Million	344,892 Added 65.87%	868,479 $45.2 Million
Q3 2020 Nov 16, 2020	BUY	$18.49 - $27.24 $4.87 Million - $7.18 Million	263,544 Added 101.35%	523,587 $14 Million
Q2 2020 Aug 14, 2020	SELL	$8.9 - $21.84 $194,465 - $477,204	-21,850 Reduced 7.75%	260,043 $5.07 Million
Q1 2020 May 15, 2020	SELL	$7.14 - $15.99 $4.31 Million - $9.66 Million	-604,195 Reduced 68.19%	281,893 $2.77 Million
Q4 2019 Feb 14, 2020	BUY	$5.1 - $11.2 $3.61 Million - $7.92 Million	707,522 Added 396.22%	886,088 $9.84 Million
Q3 2019 Nov 14, 2019	BUY	$5.38 - $8.99 $487,949 - $815,366	90,697 Added 103.22%	178,566 $1 Million
Q2 2019 Aug 14, 2019	SELL	$6.27 - $8.65 $1.16 Million - $1.61 Million	-185,698 Reduced 67.88%	87,869 $760,000
Q1 2019 May 15, 2019	BUY	$4.02 - $8.04 $806,223 - $1.61 Million	200,553 Added 274.68%	273,567 $2.2 Million
Q4 2018 Feb 14, 2019	BUY	$3.44 - $5.76 $201,491 - $337,380	58,573 Added 405.6%	73,014 $300,000
Q3 2018 Nov 14, 2018	SELL	$5.15 - $14.0 $1.25 Million - $3.4 Million	-243,133 Reduced 94.39%	14,441 $81,000
Q2 2018 Aug 14, 2018	BUY	$12.5 - $15.0 $775,625 - $930,750	62,050 Added 31.74%	257,574 $3.39 Million
Q1 2018 May 15, 2018	BUY	$8.7 - $16.8 $933,101 - $1.8 Million	107,253 Added 121.5%	195,524 $2.78 Million
Q4 2017 Feb 14, 2018	SELL	$7.35 - $12.3 $375,474 - $628,345	-51,085 Reduced 36.66%	88,271 $724,000
Q3 2017 Nov 14, 2017	BUY	$10.0 - $12.7 $1.39 Million - $1.77 Million	139,356	139,356 $1.65 Million

Others Institutions Holding TGTX

# of Institutions

269

Shares Held

87.7M

Call Options Held

2.72M

Put Options Held

1.74M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $2.73B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account